Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Real-time Estimate Cboe BZX Other stock markets 12:41:39 2024-06-10 pm EDT			5-day change	1st Jan Change
12.02 ^USD	+0.38%		-0.58%	+75.95%

Jun. 05	Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer	CI
Jun. 01	Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting	Jun. 07	AQ
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer	Jun. 05	AQ
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting	Jun. 01	AQ
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting	Jun. 01	AQ
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments	May. 07	AQ
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	Apr. 26	AQ
Y-mAbs to Present at 2024 ASCO Annual Meeting	Apr. 25	AQ
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	Mar. 14	AQ
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	Mar. 04	AQ
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	Mar. 04	PU
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	Feb. 29	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024	Feb. 16	AQ
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index	Dec. 13	AQ
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	Nov. 13	AQ
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023	23-10-31	AQ
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director	23-10-18	AQ
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA	23-10-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Press Releases

Filters